Table 3.
Association of the dichotomized SAI QRST with composite HF endpoint.
| Univariable Cox regression | Multivariable Cox regression | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95 CI | P-value | HR | 95 CI | P-value |
| Age at implant (years) | 1.01 | 1.0–1.02 | 0.16 | 1.02 | 0.99–1.0 | 0.11 |
| Ischemic cardiomyopathy | 1.6 | 1.2–2.1 | 0.002 | 1.1 | 0.78–1.6 | 0.56 |
| Women | 1 | 0.74–1.5 | 0.78 | |||
| Left ventricular ejection fraction (%) | 0.98 | 0.96–1.0 | 0.09 | 0.97 | 0.95–1.0 | 0.03 |
| QRS duration (ms) | 0.99 | 0.99–1.0 | 0.01 | 0.998 | 0.99–1.0 | 0.54 |
| Left bundle branch block | 0.79 | 0.61–1.0 | 0.08 | 0.928 | 0.62–1.4 | 0.715 |
| NYHA class | 2.4 | 1.7–3.3 | <0.001 | 1.6 | 1.2–2.2 | 0.003 |
| S-Creatinine (mg/dL) | 1.5 | 1.2–1.9 | 0.001 | 1.3 | 1.00–1.7 | 0.047 |
| Diabetes mellitus | 1.3 | 1.0–1.7 | 0.03 | 1.3 | 0.97–1.8 | 0.08 |
| Atrial fibrillation | 1.3 | 1.0–1.7 | 0.02 | 1.1 | 0.82–1.5 | 0.46 |
| Previous stroke / TIA | 1.1 | 0.77–1.7 | 0.51 | |||
| Loop diuretic treatment | 2.3 | 1.2–4.1 | 0.009 | 2.2 | 1.2–4.3 | 0.02 |
| Beta-blocker | 0.73 | 0.53–1.0 | 0.064 | |||
| ACEi/ARB | 0.65 | 0.41–1.0 | 0.07 | 0.75 | 0.41–1.4 | 0.36 |
| Cardiac resynchronization therapy defibrillator | 0.88 | 0.67–1.21 | 0.36 | 1.02 | 0.99–1.0 | 0.11 |
| SAI QRST <302mV*ms | 1.70 | 1.4 – 2.1 | < 0.001 | 1.60 | 1.1–2.20 | 0.01 |
TIA= transient ischemic attack, ACEi= angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor blocker, NYHA=New York Heart Association classification of heart failure, SAI QRST = summed absolute QRST integral.